A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...

Request To Download Free Sample of This Strategic Report @ Introduction Spinal Muscular Atrophy (SMA) is a rare genetic disorder characterized by the progressive loss of motor neurons, leading to ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.

SPINRAZA is an approved treatment for spinal muscular atrophy ... the underlying cause of motor neuron loss by continuously increasing the amount of full-length survival motor neuron (SMN) protein ...

Analytics company GlobalData has shared its optimism regarding the future of Novartis’ spinal muscular atrophy ... biallelic mutations in the survival motor neuron 1 (SMN1) gene.

MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

Biogen’s applications for the higher dose regimen of spinal muscular atrophy (SMA) drug Spinraza are now under review in the US and Europe.

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

Laboratory tests can monitor for renal toxicity and coagulation abnormalities, including acute severe low platelet counts, which have been observed after administration of some ASOs. Biogen licensed ...